Browsing by Author "Petrović, Nina (7006674563)"

Introduction/Objective Spinal anesthesia (SA) for cesarean section may lead to significant changes in hemodynamic parameters, especially hypotension. The aim of this study was to determine and compare the efficacy and safety of preemptive infusion protocols of the two most commonly used vasopressors, ephedrine (Group E, n = 29) and phenylephrine (Group P, n = 31) not only on prevention of hypotension but also to determine their effect on hemodynamic parameters, such as stroke volume (SV) and cardiac output (CO) using a continuous non-invasive hemodynamic monitor. Methods The infusion of ephedrine was administered at the rate of 5 mg/min. immediately after SA. Phenylephrine was administered at an infusion rate of 25 μg/min for two minutes prior to SA. Results In Group E, mean systolic blood pressure (SBP) and heart rate (HR) were similar to baseline. CO was higher (p < 0.001), while systemic vascular resistance (SVR) was lower than baseline (p < 0.001). In Group P, mean SBP and diastolic blood pressure (DBP) were lower than baseline, respectively (p = 0.006, p < 0.001). SBP, DBP, CO, SV, SVR, and HR were significantly different between the E and P groups (p < 0.001). Conclusion E and P vasopressors are both effective in the prevention of hypotension during SA. © 2020, Serbia Medical Society. All rights reserved.

Introduction/Objective Isocitrate dehydrogenase (IDH) mutations play a significant role in gliomagenesis. Specific microRNAs, such as microRNA-10b and microRNA-21, act as oncogenic microRNAs, whereas microRNA-34a acts as a tumor suppressor in glioblastoma. Our study aimed to investigate whether the IDH1 mutation status correlates with microRNA-10b,-21, and-34a expression levels in patients with glioblastoma. Methods The study included 43 patients diagnosed with glioblastoma. We examined microRNA-10b,-21, and-34a expression levels in peripheral blood mononuclear cells after surgery and prior to concurrent radiotherapy with temozolomide, as well as at the 15th and 30th fractions of radiotherapy with temozolomide. Data on IDH1 mutation status were gathered from medical histories and histopathology. Results Two groups were created to assess the association of microRNA-10b,-21, and-34a expression levels: glioblastoma IDH1-wildtype and glioblastoma IDH1-mutant + not otherwise specified (NOS). The median microRNA-10b expression level before the initiation of concurrent radiotherapy with temozolomide was 130.44 (52.2–622.53) in the IDH1-wildtype group and 94.61 (2.13–816.89) in the IDH1-mutant + NOS group. The median microRNA-21 expression level was 57.16 (2.68–278.98) in the IDH1-wildtype group and 69.74 (4.6–825.43) in the IDH1-mutant + NOS group. The median microRNA-34a expression level was 13.52 (3.16–105.20) in the IDH1-wildtype group and 10.11 (1–210.55) in the IDH1-mutant + NOS group. The results showed no statistically significant difference in the expression levels of microRNA-10b,-21, or-34a between the two groups (p > 0.05). Conclusion Our findings suggest that IDH1 mutation status may not be a critical factor for altered expression of microRNA-10b,-21, and-34a in glioblastoma patients. © 2025, Serbia Medical Society. All rights reserved.

Introduction/Objective Despite frequent side effects such as hypotension, spinal anesthesia (SA) is still one of the best anesthetic methods for elective cesarean section (CS). Intermittent, oscillometric, non-invasive blood pressure monitoring (NIBP) frequently leads to missed hypotensive episodes. The objective was to compare continuous non-invasive arterial pressure (CNAP) monitoring with NIBP in the terms of efficiency to detect hypotension. Methods In this study, we compared CNAP and NIBP monitoring for hypotension detection in 76 patients divided into two groups of 38 patients treated with ephedrine (E) or phenylephrine (P), during three-minute intervals, starting from SA, by the end of the surgery. Results In E group, significantly lower mean systolic blood pressure (SBP) values with CNAP compared with NIBP (p = 0.008) was detected. By monitoring CNAP, we detected 31 (81.6%) hypotensive patients in E group and significantly lower number, 20 (52.6%), with NIBP (p = 0.001), while in P group CNAP detected 34 patients (89.5%) and NIBP only 18 (47.3%), p = 0.001. By monitoring CNAP, we detected significantly higher number of hypotensive intervals in E and P groups (p < 0.001). Umbilical vein pH was lower within hypotensive compared with normotensive patients in E and P groups, with CNAP and NIBP, respectively (p < 0.001, p = 0.027 in E, and p = 0.009, p < 0.001, in P group). Conclusion CNAP is more efficient in hypotension detection for CS during SA, which allows faster treatment of hypotension, thus improving fetal and maternal outcome. © 2021, Serbia Medical Society. All rights reserved.

Background: Precise molecular characterization of breast cancer, especially triple negative (TNBC) as the most lethal subtype, is needed to stratify patients for the individual treatment approach. MicroRNA-205 (miR-205) has tumor-suppressive and oncogenic functions across different cancers. Therefore, miR-205 might have a different role in TNBC and estrogen receptor (ER) positive BC. Our aim was to investigate how miR-205 expression is associated with ER/progesteron receptor status, clinical parameters, pathohistological characteristics of BC, and survival of patients Methods: We determined miR-205 relative expressions in 73 primary breast tumors (50 TNBC and 23 ER+) by quantitative Real-time polymerase chain reaction (qPCR) and compared it to clinicopathological characteristics and outcome. Results: The highest levels of miR-205 were in the ER+ /PR+ group, and the lowest in the TNBC group (p = 0.009). Significantly higher levels of miR-205 were also observed in the ER+ compared with the ER-negative group, regardless of the PR status (p = 0.002). Low miR-205 expression level was associated with prognostic stage III in TNBC samples (p = 0.049). Patients who received adjuvant chemotherapy had significantly lower levels of miR-205 (p = 0.016). Patients who received hormone therapy had significantly higher levels of miR-205 (p = 0.007). The low-miR-205 patients had significantly higher 5-year survival rates (p = 0.041). Conclusion: The expression of miR-205 in BC is subtype-specific and high expression is associated with the ER+ tumors. The miR-205 expression might be a useful marker of TNBC progression. High miR-205 expression had a detrimental effect on BC patient outcome. Our results indicate that miR-205 might be utilized in clinical practice as a biomarker and an adjunct parameter for the selection of the most effective therapeutic modality. © 2022 Elsevier GmbH

Background: Precise molecular characterization of breast cancer, especially triple negative (TNBC) as the most lethal subtype, is needed to stratify patients for the individual treatment approach. MicroRNA-205 (miR-205) has tumor-suppressive and oncogenic functions across different cancers. Therefore, miR-205 might have a different role in TNBC and estrogen receptor (ER) positive BC. Our aim was to investigate how miR-205 expression is associated with ER/progesteron receptor status, clinical parameters, pathohistological characteristics of BC, and survival of patients Methods: We determined miR-205 relative expressions in 73 primary breast tumors (50 TNBC and 23 ER+) by quantitative Real-time polymerase chain reaction (qPCR) and compared it to clinicopathological characteristics and outcome. Results: The highest levels of miR-205 were in the ER+ /PR+ group, and the lowest in the TNBC group (p = 0.009). Significantly higher levels of miR-205 were also observed in the ER+ compared with the ER-negative group, regardless of the PR status (p = 0.002). Low miR-205 expression level was associated with prognostic stage III in TNBC samples (p = 0.049). Patients who received adjuvant chemotherapy had significantly lower levels of miR-205 (p = 0.016). Patients who received hormone therapy had significantly higher levels of miR-205 (p = 0.007). The low-miR-205 patients had significantly higher 5-year survival rates (p = 0.041). Conclusion: The expression of miR-205 in BC is subtype-specific and high expression is associated with the ER+ tumors. The miR-205 expression might be a useful marker of TNBC progression. High miR-205 expression had a detrimental effect on BC patient outcome. Our results indicate that miR-205 might be utilized in clinical practice as a biomarker and an adjunct parameter for the selection of the most effective therapeutic modality. © 2022 Elsevier GmbH

A growing body of evidence suggests a role of the von Hippel–Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up- or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069–0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109–19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = − 0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified. © 2017, Springer Science+Business Media, LLC, part of Springer Nature.

A growing body of evidence suggests a role of the von Hippel–Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up- or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069–0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109–19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = − 0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified. © 2017, Springer Science+Business Media, LLC, part of Springer Nature.

Introduction/Objective In glioblastoma, upregulation of oncogenic microRNA-10b (miR-10b) and microRNA-21 (miR-21) is often found. Our study aimed to investigate whether there is a link between miR-10b and miR-21 expression levels and tumor size and tumor localization. Methods The research involved 43 patients diagnosed with glioblastoma. We analyzed the expression levels of miR-10b and miR-21 post-surgery. The data on tumor size and tumor localization were obtained from magnetic resonance imaging. Results The median expression level of miR-10b in patients with tumors < 4 cm was 214.86 (min–max: 2.13–816.89), while in patients with tumors ≥ 4 cm, the median expression level was 92.99 (min–max: 19.24–491.82). The median expression level of miR-21 in patients with tumors < 4 cm was 81.69 (min– max: 11.39–825.43), whereas in patients with tumors ≥ 4 cm, the median expression level was 40.84 (min–max: 2.68–278.98). For both miR-10b and miR-21, a statistically significant difference was found for tumors < 4 cm (p = 0.027 and p = 0.047, respectively) compared to those ≥ 4 cm. There was no statistically significant difference in the expression levels of miR-10b (p = 0.675) and miR-21 (p = 0.183) in relation to tumor localization. Conclusion Glioblastomas smaller than 4 cm have statistically significantly higher expression levels of miR-10b and miR-21 compared to glioblastomas equal to or larger than 4 cm. Although this result is unexpected, it could mean that miR expression levels dynamically change after surgery and according to the altered microenvironment. © 2025, Serbia Medical Society. All rights reserved.

Purpose: More than half of prostate cancer patients undergo radiation treatment which may be accompanied by acute or late side effects in genitourinary, GU, and/or gastrointestinal, GI tract, and radiotherapy-induced fatigue (RIF). The biological role of RNase L highlights its potential to be tested for association with the adverse effects of radiotherapy. Objectives: This study aims to investigate the associations among RNASEL gene variants, acute, late GI/GU toxicity events, and RIF to evaluate their potential to be used as biomarkers for prediction of response to radiation treatment. Methods: The DNA from peripheral blood mononuclear cells of 81 patients with prostate adenocarcinoma under RT was genotyped for RNASEL rs12757998, rs486907, and rs627928 by real-time quantitative PCR. The acute and late GU and GI adverse effects were evaluated during and up to 54 months after RT, as well as the occurrence or increase in fatigue grade. Results: rs12757998 RNASEL TT genotype was shown to be significantly associated with severity of acute GU toxicity while CT genotype with severity of late GI toxicity. Furthermore, CC genotype of rs12757998 and the AA genotype of rs627928 were shown to be potential independent predictive biomarkers of RIF. Conclusion: RNASEL gene polymorphisms are associated with a higher risk of radiotoxicity, which may be used for biological tests for the prediction of RT-related side effects and to develop strategies to fight against fatigue, to significantly improve the quality of life of cancer survivors. © Copyright © 2025 Taylor & Francis Group LLC.